Effect of synthetic peptide cSN50.1 on the malignant behavior of hepatocellular carcinoma HepG2 cells and its mechanism

Hua XIN; Hongchao SHAN; Haiyan LUAN; Yang RUAN; Xinyan YANG

doi:10.3969/j.issn.1001-5256.2023.10.014

Volume 39 Issue 10

Oct. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(10): 2366-2374

PDF( 1783 KB)

Effect of synthetic peptide cSN50.1 on the malignant behavior of hepatocellular carcinoma HepG2 cells and its mechanism

DOI: 10.3969/j.issn.1001-5256.2023.10.014

Hua XIN¹,
Hongchao SHAN¹,
Haiyan LUAN²,
Yang RUAN^{3
,
,
,},
Xinyan YANG^{2
,
,
,}

1.
The First Affiliated Hospital of Jiamusi University，Jiamusi，Heilongjiang 154007，China
2.
School of Basic Medical Sciences，Jiamusi University，Jiamusi，Heilongjiang 154007，China
3.
The Central Hospital of Jiamusi City，Jiamusi，Heilongjiang 154002，China

Research funding:

Project of Health Department of Heilongjiang Province (20210404010187);

Jiamusi University Youth Innovative Talent Training Support Program (JMSUQP2021016);

Basic Scientific Research Operating Expenses Team Project of Heilongjiang Provincial Colleges and Universities (2022－KYYWF－0656)

More Information

Corresponding author: RUAN Yang， 88584060@qq.com （ORCID： 0000－0002－9802－120X）; YANG Xinyan， yangxinyan5464@163.com （ORCID： 0000－0003－0819－6768）
Received Date: 2022-11-08
Published Date: 2023-10-30

Abstract

Abstract

Objective To investigate the effect of cSN50.1 on the proliferation， migration， invasion， and colony formation of HepG2 cells and its mechanism. Methods HepG2 cells were divided into cSN50.1 0 μmol/L， cSN50.1 10 μmol/L， cSN50.1 30 μmol/L， cSN50.1 50 μmol/L， cSN50.1 70 μmol/L， and cSN50.1 90 μmol/L groups， and CCK－8 assay was used to investigate the effect of different concentrations of cSN50.1 on the proliferation of HepG2 cells and calculate half－maximal inhibitory concentration （IC₅₀）. HepG2 cells were divided into cSN50.1 0 μmol/L， cSN50.1 10 μmol/L， cSN50.1 30 μmol/L， and cSN50.1 50 μmol/L groups， and wound healing assay， Transwell assay， and colony－forming assay were used to investigate the effect of different concentrations of cSN50.1 on the migration， invasion， and colony formation of HepG2 cells. HepG2 cells were divided into Control group， SP600125 group （an inhibitor of the AP－1 signaling pathway）， and cSN50.1 group to investigate the influence of the AP－1 signaling pathway on the effect of cSN50.1 on hepatocellular carcinoma cells， and RT－PCR and Western Blot were used to measure the expression of CXCL5， TNF－α， and c－Jun protein in cytoplasm and nucleus. HepG2 cells were divided into Control group， PDTC group （an inhibitor of the NF－κB signaling pathway）， and cSN50.1 group to investigate the influence of the NF－κB signaling pathway on the effect of cSN50.1 on hepatocellular carcinoma cells， and RT－PCR and Western Blot were used to measure the expression of CXCL5， TNF－α， and NF－κB protein in cytoplasm and nucleus. A one－way analysis of variance was used for comparison between multiple groups， and the SNK－q test was used for further comparison between two groups. Results Compared with the 0 μmol/L group， the 10 μmol/L group had no significant changes in proliferation， migration， invasion， and colony formation abilities （P >0.05）； the 30 μmol/L group had no significant change in proliferation ability （P>0.05）， but with significant reductions in migration， invasion， and colony formation abilities （P<0.05）； the 50 μmol/L group had significant reductions in proliferation， migration， invasion， and colony formation abilities （all P<0.01）； the 70 μmol/L and 90 μmol/L groups had a significant reduction in cell proliferation ability （P<0.01）， but with a cell survival rate of below 50%. Compared with the Control group， the SP600125， PDTC， and cSN50.1 groups had significant reductions in the mRNA and protein expression levels of CXCL5 and TNF－α （all P<0.05）. Compared with the Control group， the SP600125 group， the PDTC group， and the cSN50.1 group had a significant reduction in nuclear protein of c－Jun and NF－κB expression （P<0.05）； the SP600125 group and the PDTC group had a significant reduction in cytoplasmic protein of c－Jun and NF－κB expression （P<0.05）； the cSN50.1 group had a significant increase in cytoplasmic protein of c－Jun and NF－κB expression （P<0.05）. Conclusion This study shows that cSN50.1 can inhibit the malignant behavior of hepatocellular carcinoma cells and reduce the expression of CXCL5 and TNF－α by inhibiting the nuclear import of c－Jun and NF－κB in hepatocellular carcinoma cells.
- Liver Neoplasms,
- cSN50.1,
- Tumor Necrosis Factor－alpha,
- Chemokine CXCL5,
- Active Transport， Cell Nucleus

FullText(HTML)

References(27)

References

[1]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68( 6): 394－ 424. DOI: 10.3322/caac.21492.
[2]	2019 Under－ GBD 5 Mortality Collaborators. Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: All－cause and cause－specific mortality findings from the Global Burden of Disease Study 2019[J]. Lancet, 2021, 398( 10303): 870－ 905. DOI: 10.1016/S0140－6736(21)01207－1.
[3]	VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380( 15): 1450－ 1462. DOI: 10.1056/nejmra1713263.
[4]	LI X, RAMADORI P, PFISTER D, et al. The immunological and metabolic landscape in primary and metastatic liver cancer[J]. Nat Rev Cancer, 2021, 21( 9): 541－ 557. DOI: 10.1038/s41568－021－00383－9.
[5]	LEE G, HAN SB, LEE JH, et al. Cancer mechanobiology: Microenvironmental sensing and metastasis[J]. ACS Biomater Sci Eng, 2019, 5( 8): 3735－ 3752. DOI: 10.1021/acsbiomaterials.8b01230.
[6]	VEACH RA, LIU Y, ZIENKIEWICZ J, et al. Survival, bacterial clearance and thrombocytopenia are improved in polymicrobial sepsis by targeting nuclear transport shuttles[J]. PLoS One, 2017, 12( 6): e0179468. DOI: 10.1371/journal.pone.0179468.
[7]	ALTEKRUSE SF, MCGLYNN KA, REICHMAN ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005[J]. J Clin Oncol, 2009, 27( 9): 1485－ 1491. DOI: 10.1200/JCO.2008.20.7753.
[8]	SCHLEIN LJ, THAMM DH. Review: NF－kB activation in canine cancer[J]. Vet Pathol, 2022, 59( 5): 724－ 732. DOI: 10.1177/03009858221092017.
[9]	YANG Y, LI TF, HUANG C. Research progress of tumor stroma ingredient and pathological features in gastric cancer[J]. Chin J Dig Surg, 2022, 21( 3): 427- 432. DOI: 10.3760/cma.j.cn115610-20220216-00090. 杨彦, 李腾飞, 黄陈. 肿瘤间质成分及病理学特征在胃肿瘤中的研究进展[J]. 中华消化外科杂志, 2022, 21( 3): 427- 432. DOI: 10.3760/cma.j.cn115610-20220216-00090.
[10]	KWON OS, CHOI SH, KIM JH. Inflammation and hepatic fibrosis, then hepatocellular carcinoma[J]. Korean J Gastroenterol, 2015, 66( 6): 320－ 324. DOI: 10.4166/kjg.2015.66.6.320.
[11]	CHEN H, ZHOU XH, LI JR, et al. Neutrophils: Driving inflammation during the development of hepatocellular carcinoma[J]. Cancer Lett, 2021, 522: 22－ 31. DOI: 10.1016/j.canlet.2021.09.011.
[12]	PETRICK JL, FLORIO AA, ZNAOR A, et al. International trends in hepatocellular carcinoma incidence, 1978–2012[J]. Int J Cancer, 2020, 147( 2): 317－ 330. DOI: 10.1002/ijc.32723.
[13]	TANG A, HALLOUCH O, CHERNYAK V, et al. Epidemiology of hepatocellular carcinoma: Target population for surveillance and diagnosis[J]. Abdom Radiol, 2018, 43( 1): 13－ 25. DOI: 10.1007/s00261－017－1209－1.
[14]	SINGAL AG, LAMPERTICO P, NAHON P. Epidemiology and surveillance for hepatocellular carcinoma: New trends[J]. J Hepatol, 2020, 72( 2): 250－ 261. DOI: 10.1016/j.jhep.2019.08.025.
[15]	YE DY, YANG S, ZHAO LL, et al. Research progress in effects of inflammatory markers on occurrence, development and prognosis of malignant tumors and their mechanisms[J]. J Jilin Univ(Med Ed), 2022, 48( 4): 1079－ 1087. DOI: 10.13481/j.1671－587X.20220432. 叶德宇, 杨帅, 赵龙龙, 等. 炎性标志物对恶性肿瘤发生发展和预后的影响及其机制的研究进展[J]. 吉林大学学报(医学版), 2022, 48( 4): 1079－ 1087. DOI: 10.13481/j.1671－587X.20220432.
[16]	RICHARDSON JSM, AMINUDIN N, MALEK SN ABD. Chalepin: A compound from Ruta angustifolia L. pers exhibits cell cycle arrest at S phase, suppresses nuclear factor－kappa B(NF－κB) pathway, signal transducer and activation of transcription 3(STAT3) phosphorylation and extrinsic apoptotic pathway in non－small cell lung cancer carcinoma(A549)[J]. Pharmacogn Mag, 2017, 13( Suppl 3): S489－S498. DOI: 10.4103/pm.pm_13_17.
[17]	VERMA A, SINGH D, ANWAR F, et al. Triterpenoids principle of Wedelia calendulacea attenuated diethynitrosamine－induced hepatocellular carcinoma via down－regulating oxidative stress, inflammation and pathology via NF－kB pathway[J]. Inflammopharmacology, 2018, 26( 1): 133－ 146. DOI: 10.1007/s10787－017－0350－3.
[18]	REN ZR, CHEN Y, SHI L, et al. Sox9/CXCL5 axis facilitates tumour cell growth and invasion in hepatocellular carcinoma[J]. FEBS J, 2022, 289( 12): 3535－ 3549. DOI: 10.1111/febs.16357.
[19]	JIA XQ, WEI SQ, XIONG WJ. CXCL5/NF－κB pathway as a therapeutic target in hepatocellular carcinoma treatment[J]. J Oncol, 2021, 2021: 9919494. DOI: 10.1155/2021/9919494.
[20]	ZHOU SL, DAI Z, ZHOU ZJ, et al. CXCL5 contributes to tumor metastasis and recurrence of intrahepatic cholangiocarcinoma by recruiting infiltrative intratumoral neutrophils[J]. Carcinogenesis, 2014, 35( 3): 597－ 605. DOI: 10.1093/carcin/bgt397.
[21]	XIA JL, XU XJ, HUANG PX, et al. The potential of CXCL5 as a target for liver cancer－what do we know so far?[J]. Expert Opin Ther Targets, 2015, 19( 2): 141－ 146. DOI: 10.1517/14728222.2014.993317.
[22]	PAN LC, XIAO HY, YIN WJ, et al. Correlation between HSD17B4 expression in rat liver cancer tissues and inflammation or proliferation[J]. Eur Rev Med Pharmacol Sci, 2018, 22( 11): 3386－ 3393. DOI: 10.26355/eurrev_201806_15160.
[23]	YANG YM, KIM SY, SEKI E. Inflammation and liver cancer: Molecular mechanisms and therapeutic targets[J]. Semin Liver Dis, 2019, 39( 1): 26－ 42. DOI: 10.1055/s－0038－1676806.
[24]	XING Y, LIU Y, QI Z, et al. LAGE3 promoted cell proliferation, migration, and invasion and inhibited cell apoptosis of hepatocellular carcinoma by facilitating the JNK and ERK signaling pathway[J]. Cell Mol Biol Lett, 2021, 26( 1): 49. DOI: 10.1186/s11658－021－00295－4.
[25]	BHOSALE PB, KIM HH, ABUSALIYA A, et al. Structural and functional properties of activator protein－1 in cancer and inflammation[J]. Evid Based Complementary Altern Med, 2022, 2022: 1－ 8. DOI: 10.1155/2022/9797929.
[26]	TAN WL, LUO X, LI WD, et al. TNF－α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma[J]. EBioMedicine, 2019, 40: 446－ 456. DOI: 10.1016/j.ebiom.2018.12.047.
[27]	DOLCET X, LLOBET D, PALLARES J, et al. NF－kB in development and progression of human cancer[J]. Virchows Arch, 2005, 446( 5): 475－ 482. DOI: 10.1007/s00428－005－1264－9.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(8)

Get Citation

PDF

XML

Article Metrics

Article views (122) PDF downloads(21)

Effect of synthetic peptide cSN50.1 on the malignant behavior of hepatocellular carcinoma HepG2 cells and its mechanism

DOI: 10.3969/j.issn.1001-5256.2023.10.014

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Effect of synthetic peptide cSN50.1 on the malignant behavior of hepatocellular carcinoma HepG2 cells and its mechanism

DOI: 10.3969/j.issn.1001-5256.2023.10.014

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content